LSM with a known etiology shows better therapeutic outcomes, as riboflavin-responsive MADD (RR-MADD) with ETFDH mutation and carnitine-responsive PCD with SLC22A5 mutation. This evidence concerns the gene SLC22A5 and multiple acyl-CoA dehydrogenase deficiency.